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Abstract: The operative management of giant pituitary prolactinoma represents a 
significant challenge for neurosurgeons, due to the degree of local tumor infiltration into 
adjacent structures such as cavernous sinus. The degree of parasellar tumor extension 
can be classified according to the Knosp grading system’ while suprasellar extension is 
qualified in accordance with the modified Hardys classification system. This report 
describes the case of a male patient with a giant pituitary prolactinoma in which a partial 
tumor resection via a subfrontal approach was achieved. Typically, resection rates of less 
than 50% have been reported following surgery on giant pituitary adenomas. Prolactin 
levels were very high, consistent with invasive giant prolactinoma. Our patient was 
treated with Cabergoline which eventually normalized the prolactin level and 
significantly reduced the size of the residual tumor. This case serves to illustrate that in 
the presence of significant suprasellar and parasellar extension, multi-modal treatment 
strategies with surgery and dopamine agonist, is the gold standard in the management 
of locally aggressive pituitary prolactinomas. 
 
Introduction 
Pituitary adenomas are considered to be 
benign tumors and account for about 15% of 
primary intracranial tumors (14). Tumors 
exceeding 10 mm are defined as 
macroadenomas, and those smaller than 10 
mm are termed microadenomas (14). While 
microadenomas are located within the sella 
and do not cause visual loss, macroadenomas 
extend beyond the limits of the sella and may 
cause neuro-ophthalmologic manifestations 
by compression of adjoining structures (3). 
Giant pituitary adenomas, defined as tumors 4 
cm or greater in maximum diameter, account 
for 5%-14% of adenomas in surgical series (12, 
18, 20). 
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Prolactinomas account for approximately 
30% of pituitary adenomas and 50 to 60% of 
functional pituitary tumors (25). They are the 
most common type of functioning pituitary 
tumor and are second in frequency to 
nonfunctioning adenomas in overall 
incidence. Men tend to present with a larger, 
more invasive and rapid growth 
prolactinomas than women, possibly because 
hypogonadism features are less evident (6).  
The degree of radical resection of giant 
adenomas is restricted to less than 50% in 
every published surgical study and is 
associated with a higher complication rate 
compared with non-giant pituitary adenomas 
(12, 18, 20). The most common surgical 
approaches used for the treatment of giant 
pituitary prolactinomas are the microscopic 
transsphenoidal or various frontal and 
frontotemporal transcranial routes (12, 17, 18, 
20). Additional therapies are usually necessary 
to obtain long-term control of tumor growth 
(18, 20). Current recommendations suggest 
Dopamine agonists as the treatment of choice 
for prolactinomas, including giant and 
invasive types as these drugs suppresses 
prolactin (PRL) secretion and synthesis as well 
as lactotrope cell proliferation (24). 
We presented the case of a giant pituitary 
prolactinoma, which infiltrate the dura and 
cavernous sinus. We performed a subtotal 
resection through a subfrontal approach 
followed by dopamine agonist treatment. This 
combined treatment was very effective in 
normalizing serum PRL levels and shrinking 
the tumor size. 
 
Case presentation 
We presented the case of a 61 years old 
male patient, admitted in our clinic with a one 
year history of a reduction in his peripheral 
visual field. This was associated with a shorter 
history of gradual loss of movements and poor 
vision in the right eye, frontal headache and 
unsteady gait. Prior to his admission he 
consulted an ophthalmologist with complaint 
of double vision. Ophthalmological 
examination revealed important loss of visual 
acuity, especially in the right eye, a bilateral 
superior temporal quadrantanopsia and 
medial convergent squint due to the right sixth 
cranial nerve palsy. As his psychic was 
concerned, the patient was alert and oriented. 
A subsequent cerebral magnetic resonance 
imaging (MRI) scan showed a giant 
(28/43mm.) enhancing tumor expanding in 
the pituitary fossa and extending into the 
suprasellar cistern (Figure 1). The tumor, 
which demonstrated a relative homogenous 
enhancement, encased the right optic nerve 
and showed a lobular extension into the right 
sylvian fissure, invasion of the right cavernous 
sinus enclosing the cavernous carotid artery. 
The tumor elevated the floor of the third 
ventricle, extended to the perimesencephalic 
cisterns and contacted the right pons. The 
anterior vascular arcade (both A1 segments of 
the anterior cerebral arteries and anterior 
communicating artery) were displaced 
posteriorly. 
The degree of parasellar tumor extension 
was classified according to the Knosp grading 
system (grade 4), while suprasellar extension 
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was qualified in accordance to the Hardys 
classification system (grade C). 
Because of the irregular shape of the tumor 
and its extension into the subfrontal region, 
retrochiasmatic area and sylvian fissure we 
chose to perform a transcranial approach for 
this case. The patient underwent a subtotal 
tumor resection via a right subfrontal 
approach, achieving an approximately 30% 
reduction in tumor bulk, with focus on right 
optic nerve decompression.  
Postoperatively, the patient’s bilateral 
superior quadrantanopsia improved and his 
headache resolved, but he developed diabetes 
insipidus. There were no other operative 
complications. The histopathological exam 
revealed a pituitary prolactinoma. 
Preoperatively, laboratory studies revealed 
prolactin 4700 ng/ml (4.60-21.40), cortisol 
1.64 μg/dl (6.2-19.4), testosterone 0.025 ng/ml 
(1.93-7.40), TSH 0.097uUI/ml (0.27-4.20), low 
free thyroxine (fT4) 0.617 μg/dl (0.93-1.7). 
After surgery, beside the substitutional 
hormonal therapy, the patient started medical 
treatment with Cabergoline (Dostinex), a 
dopamine agonist, 0.25 mg twice per week, 
with gradual increase in the dose to 1 mg twice 
a week. After 3 weeks of endocrine treatment, 
laboratory studies revealed an important 
decrease in prolactin level to value of 343.50 
ng/ml. 
After his discharge from hospital, the 
patient continued his treatment with 
Cabergoline, which eventually normalized the 
prolactine level and significantly reduce the 
size of the tumor rest. 
MRI images, obtained 5 months after 
surgery, showed important reduction of the 
tumor’s size. The right pons, the right 
temporal lobe and the floor of the third 
ventricle were completely decompressed 
(Figure 2). There is still residual tumor in the 
right cavernous sinus. The visual symptoms 
were improved and the follow-up MRI, 10 
months after surgery, demonstrated that 
residual tumor has continued to collapse and 
minimize, under dopamine agonist therapy 
(Figure 3). 
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Figure 1 - Preoperative axial (a1, a2, a3) and coronal 
(a4) MRI images after contrast administration 
showed a giant (28/43 mm), homogenous tumor, 
which invaded the right cavernous sinus, extended 
over the upper clivus and in the temporal lobe, and 
elevated the floor of the third ventricle 
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Figure 2 - Images obtained 5 months after surgery 
and cabergoline treatment. Axial (b1, b2, b3) and 
coronal (b4) MRI images showed important 
reduction of the tumor’s size. The right pons, the 
right temporal lobe and the floor of the third 
ventricle were completely decompressed 
Discussion 
Giant macroadenomas are defined as 
lesions greater than 4cm in diameter and 
represent till 14-15% of all pituitary adenomas 
(20). Since the original description of this 
pathological entity by Jefferson in the 1940s, 
surgical treatment of giant pituitary adenomas 
has been extremely challenging (13). 
Postoperative mortality rates as high as 35% 
has been reported (13, 19).  Giant pituitary 
adenomas can be extremely challenging to 
manage using surgery alone. In case of giant 
prolactinoma, the use of medical therapy and, 
possibly, radiation therapy, is crucial for 
achieving long-term tumor control.  
The main goals of surgery for giant 
pituitary adenomas are visual improvement, 
recovery from endocrinological and 
neurological symptoms, and maximal tumor 
resection (25). Surgery, either transcranial or 
transsphenoidal approaches, is the first-line 
treatment in tumors with compression upon 
optic structures and visual impairment. The 
complexity of surgery for giant pituitary 
adenomas relate to the degree and direction of 
perisellar spread, because they tend to extend 
in either a suprasellar or parasellar trajectory 
(19). The degree of suprasellar tumor 
extension can be classified according to the 
modified Hardys classification system, while 
parasellar extension is qualified in accordance 
with the Knosp grading system (23). The 
completeness of microsurgical resection is 
inversely related to both the Hardys and 
Knosp grade of the tumor. In fact, true 
cavernous sinus invasion typically prohibits 
complete tumor resection (10, 18). It is 
generally accepted that the goal of surgical 
treatment for giant pituitary adenomas must 
be maximal tumor resection with minimal 
associated morbidity (9). 
Total resection rate of giant pituitary 
adenoma vary between different series and the 
surgical approach used. On a large series, 
Mortini et al (18) showed that total resection 
rate was 14.7%., while Goel et al. (12) showed 
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a total resection rate of 29.65%. 
Koutourousiou (15) presented a near-total 
resection rate of 66.7%. The rate of gross and 
near-total tumor removal, in cases of giant 
pituitary adenomas, after transsphenoidal, 
transcranial or combined procedures range 
from 14.7% to 74% (12, 15, 18). With recent 
advances in the expended endoscopic 
endonasal approach and the associated 
benefits of improve panoramic visualization 
afforded, these resection rates will improve. 
The limitation of endoscopic endonasal 
approach is invasion of the lateral wall of the 
cavernous sinus and extension of the tumor to 
the temporal lobe. But, despite all this, as in 
our case, an open craniotomy may still be 
indicated in patients with dumbbell tumors 
extending far into the anterior cranial fossa, 
middle fossa or retro-chiasmatic space (13). 
Safe complete resection of a giant pituitary 
adenoma lateral to the carotid artery remains 
nearly impossible with no regards to the 
surgical corridor used (8, 21). Gross-total 
resection of giant pituitary adenomas was 
dependent on multiple factors, and the overall 
low resection rates confirm the difficulty in 
their management. 
In our opinion, even in case of giant 
pituitary prolactinoma, surgery could improve 
vision and its improvement is related with 
tumor resection rate. Additionally, surgery 
could significantly improve the symptoms of 
headache and dizziness. However, surgery 
may not be effective for declined sexual 
function and amenorrhea (26). It is also 
believed that visual acuity improvement is 
significant during the first two postoperative 
weeks, with no further significant 
improvement after this period, while visual 
field defects significantly improve during the 
first two weeks postoperatively and continue 
to improve for the first three months but no 
later than that (21). Maximum visual 
improvement after pituitary surgery is at three 
months postoperatively (4). Although 
postoperative visual improvement varies 
among published series, it is more likely after 
transsphenoidal than transcranial surgery, 
with rates of approximately 80% (5, 15, 18). 
Postoperative improvement of 
hypopituitarism after surgery for giant 
pituitary adenomas has not been studied in 
detail. The reported hormonal improvement 
rates of 35%-50% after transsphenoidal 
surgery are in reference to macroadenomas 
and cannot be applied to giant pituitary 
adenomas, in which hypopituitarism is usually 
long-standing and more difficult to be 
corrected after surgery (11). 
Postoperative MRI performed at different 
time points after surgery may affect the 
accuracy of tumor volume calculation. For 
example, MRI performed within the first 
postoperative week may measure the volume 
of the hematoma while MRI performed after 2 
months or later may measure the adenoma 
recurrence. 
 In general, giant pituitary adenomas have 
a higher surgical complication rate, 
highlighting the difficulty of their treatment. 
In cases of transsphenoidal or endoscopic 
endonasal approaches the most common 
complication was postoperative cerebrospinal 
fluid (CSF) leak (16.7%), necessitating 
reoperation and/or lumbar drain placement 
(15). Worsening of pituitary function occurred 
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in 16.7% of patient after endoscopic endonasal 
surgery, which is comparable to new 
endocrinopathy after microscopic 
transsphenoidal surgery and lower than new 
pituitary dysfunction after transcranial 
surgery (5, 18, 20). Diabetes insipidus is also 
another complication after surgery for giant 
adenomas. Permanent postoperative diabetes 
insipidus vary between 8.2% and 10.4% (20). 
Postoperative visual deterioration is also more 
common after transcranial than 
transsphenoidal surgery and can be as high as 
22% (9, 18). Postoperative cranial nerve 
dysfunction is a frequent complication after 
transcranial surgery for giant tumors 
involving the cavernous sinus, and it affects 
the oculomotor nerve most often (7). Other 
complication such as syndrome of 
inappropriate antidiuretic hormone, 
hydrocephalus, pulmonary embolus, or 
cerebral ischemia may occur after transcranial 
or transsphenoidal surgery (microscopic or 
endoscopic) and are not correlated directly 
with the surgical approach. Mortality rates 
after surgery are higher in giant pituitary 
adenomas compared with non-giant 
adenomas and range from 3.2% to 18.7% (16, 
18). One of the leading causes of postoperative 
death is apoplexy of the residual adenoma. 
Remarkable progress has been made with 
regards to the management of giant 
prolactionoma. Sometimes, total resection can 
be achieved with a combined 
endonasal/transcranial approach or possibly 
with a staged endoscopic endonasal approach 
(2). The ultimate goal of a combined treatment 
(surgery, radiotherapy, endocrine 
medications) is to achieve eugonadism, 
euprolactinemia status, and reduction of 
tumor size (24). While radiotherapy is not the 
usual preferred treatment because of high 
complication rates, therapy with dopamine 
agonists (Bromocriptine, Cabergoline) are 
consistently promising in regression size of the 
pituitary prolactinoma, hypogonadal status 
reversal and prolactin level correction (6,27). 
Once normalized, serum PRL levels should be 
monitored annually (1). Bromocriptine is 
started at 1.25 to 2.5 mg orally once a day and 
increased during 2 to 3 weeks to 5 to 10 mg 
daily in divided doses. Cabergoline may be 
administered at doses ranging between 0.5 and 
1.5 mg once or twice per week (1). After 
normalization of serum PRL levels, 
bromocriptine can be reduced to the smallest 
effective dose. Visual examination should be 
repeated approximately 1 month after 
initiation of therapy, and MRI should be 
repeated at 6 weeks and again at 3 months after 
initiation of treatment (24, 27). Some 10 to 
25% of patients are partially or totally resistant 
to bromocriptine (22) and 5% to 10% of 
patients are intolerant to bromocriptine 
because of side effects (3, 22). In patients with 
giant or invasive prolactinomas, pretreatment 
with a dopamine agonist may improve the 
success of subsequent surgery. Long-term 
treatment with dopamine agonists may alter 
the consistency of the tumor and make surgery 
more difficult (22). 
Stereotactic radiosurgery is an option for 
patients with prolactinomas after failed 
transsphenoidal surgery or failed medical 
therapy and may be a primary treatment for 
prolactinomas in patients who are reluctant to 
undergo long-term medical therapy or surgery 
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(22). This is not the case for a giant 
prolactinoma, in which stereotactic 
radiosurgery is only a postsurgical therapy. 
There is a risk of hypopituitarism, and there 
may be a radioprotective effect of dopamine 
agonist therapy; therefore, these medications 
should be stopped temporarily during 
radiosurgical treatment (12, 22, 24). 
Conclusions 
Prolactinoma is one of the pituitary tumors 
that significantly respond well to medical 
therapy. The main goal of surgical treatment of 
giant pituitary prolactinoma, through 
transsphenoidal or transcranial approach, is 
maximum possible tumor extirpation with 
minimal side effects. In our case, we used the 
transcranial approach, due to the dimension 
and extension of the tumor (temporal lobe and 
cavernous sinus) and the preference and 
experience of the operating team. Our patient 
improved significantly after medical 
treatment, avoiding unnecessary reoperation, 
and preventing short and long term 
complications. Multidisciplinary treatments 
should be applied during long-term follow-up 
periods for successful care and optimal 
outcomes. 
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